Clinical Trials Sponsored by Shenzhen Evergreen Medical Institute

Total 125 results

Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for MLD

Metachromatic Leukodystrophy (MLD)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

Tissue Damage | Immune Related Disorder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Beta-Thalassemia

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Genetically Modified T Cells Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for X-ALD

X-linked Adrenoleukodystrophy

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Tuberculosis | CMV Infection | EBV Infection | Adenovirus Infection | Fungus Infection | Pathogen Infection | BKV Infection

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Shenzhen Geno-Immune Medical Institute

Suspended

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Shenzhen Geno-Immune Medical Institute

Enrolling by invitation

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Glioblastoma Multiforme | Glioblastoma Multiforme of Brain

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector （TYF-IL-2Rg）

SCID, X Linked

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for CGD

Chronic Granulomatous Disease

China
Shenzhen Geno-Immune Medical Institute

Unknown

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Human Papilloma Virus

China
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

Fanconi Anemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Treating GI Cancer

Cancer

China
Shenzhen Geno-Immune Medical Institute

Withdrawn

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

NSCLC | Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immune Modulatory DC Vaccine Against Brain Tumor

Diffuse Intrinsic Pontine Glioma or Glioblastoma

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital; Shenzhen Third People's Hospital

Recruiting

Safety and Immunity of Covid-19 aAPC Vaccine

Treat and Prevent Covid-19 Infection

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital; Shenzhen Third People's Hospital

Recruiting

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Pathogen Infection Covid-19 Infection

China
Zhujiang Hospital
Shenzhen Geno-Immune Medical Institute

Withdrawn

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
Sun Yat-sen University; Shenzhen Children's Hospital

Recruiting

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

PSMA-specific CAR-T Cell Therapy

PSMA Positive Tumors or Tumor Tissues

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Shenzhen Ausa Pharmed Co.,Ltd
Peking University First Hospital; Nanfang Hospital of Southern Medical University and other collaborators

Unknown

H-Type Hypertension Precision Medicine Trial

Hypertension

China

Clinical Trials Sponsored by Shenzhen Evergreen Medical Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations